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Table 1
Pt Characteristics
Patient Characteristics N (%)
Median Age (range) 61 years(49-72)
Median Time from First ASCT (range) 49.8 months(19.2-81.9)
Race
Caucasians 13 (72%)
Others 5 (28%)
Disease status at time of ASCT
PD 9 (50%)
SD 5 (28%)
PR 1 (5.5 %)
VGPR 2 (11%)
CR 1 (5.5%)
Median creatinine clearance (range) 43.5 (5-59)
Cytogenetic Risk
Standard 10 (56%)
High Risk 4(22%)
Unknown 4 (22%)
Melphalan Dose median mg/m2( range) 140 (100-200)
{100(2pts), 140(10pts),
180(1pt), 200(4pts)}
Median CD 34 Cell dose x106/kg (range) 4.66(2.6-27.5)
Median Engraftment Day (range)
WBC 11 (9-16)
Platelets 21 (12-61)
Median Days of Hospitalization (range) 19 (11-74)
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maintenance therapy after the second ASCT is not estab-
lished, but may have contributed to the durable responses
seen in some pts assessed herein and deserves to be inves-
tigated further.264
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Approximately 20% of multiple myeloma (MM) patients (pts)
have renal dysfunction(RD) at the time of diagnosis and
somemoremay develop it during the course of their disease.
In this retrospective review we studied outcomes in pts of
different races with RD undergoing autologous stem cell
transplant (ASCT) for MM.
Between June 2005 and December 2013, we identiﬁed
107 pts withMMwith RD (creatinine clearance< 60ml/min/
1.73m2) whowere not on hemodialysis and underwent ASCT
at our institution. Of the 107 pts, 76 were caucasian(C) pts
and 31 were identiﬁed as other (O) races (25 African Amer-
ican, one Hispanic, two Middle-eastern, three Asian). There
were no statistically signiﬁcant differences in the character-
istics between the 2 groups. Approximately a quarter of the
pts received their melphalan dose on the inpatient unit in
both groups. During the hospitalization all pts received G-
CSF from Day +6 till absolute neutrophil count 1500/ml and
antimicrobial prophylaxis with norﬂoxacin, acyclovir and
ﬂuconazole.
The median follow up was 35.9 months (range, 5.1-106.3).
One patient in the C group died 98 days after ASCT and had
evidence of disease progression. There were no deaths in the
O group during the 100 days after ASCT. Table 1 shows postTable 1
Disease status at Day 100 post ASCT and Maintenance Therapy post ASCT
Caucasian (N¼76) Other (N¼31) P Value
Disease Status
CR 26 (34%) 6 (19%) 0.5
VGPR 20 (26%) 12 (38%)
PR 17 (22%) 6 (19%)
SD 7 (9%) 4 (13%)
PD 2 (3%) 2 (7%)
Not available 4 (6%) 1 (3%)
Change in Disease Status
Improved 23 (30%) 13 (42%) 0.66
Unchanged 45 (59%) 15 (48%)
Worsened 4 (6%) 2 (7%)
Not available 4 (6%) 1 (3%)
Maintenance Therapy
IMid 40 (53%) 9 (29%) 0.15
PI 2 (3%) 1 (3%)
None 29 (38%) 19 (61%)
Not Known 5 (7%) 2 (7%)
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nance therapy. There were no statistically signiﬁcant differ-
ences between the groups in disease status or change in
disease status at day 100 post ASCT. Although more patients
in the C group received maintenance therapy post ASCT, this
difference was not statistically signiﬁcant. Figures 1 and 2
show the relapse free survival (RFS)and overall survival
(OS) of both groups. The median RFS for C and O groups were
32.3 and 20.9 months (p ¼0.63, log rank), respectively. The
median OS of the C and O groups were 73.1 and 47.8 month
(p¼0.31, log rank), respectively.
Our limited experience suggests that there was no effect
of race in the post ASCT outcomes for MM pts with RD.
ASCT was safe with acceptable transplant related mortalityTable 1
C dose (mg/m2) <2000mg/m2
Median age in years (range) 64.5 (44-79)
Number of Patients 18
Median C Dose in mg/m2 (range) 1750 (1318-1983)
Median Total CD34/Kg in 10e6 (range) 14.15 (6.89-39.7)
Days to SC collection (range) 10 (10-14)
Median days of documented neutropenia (range) 1 (0-4)
Number of patients hospitalized for NF 0and good long-term outcomes for MM pts with renal dys-
function.265
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Background: G-CSF alone or C with G-CSF are most
commonly used for SC mobilization in MM. The use of C
can improve the efﬁcacy of mobilization but is associated
with increased neutropenia. It remains largely unclear how
dose levels of C in mobilization quantitatively inﬂuence the
CD34 yield and time to collection; as well as how these
outcomes were inﬂuenced by patient’s age. We evaluated
the efﬁcacy and neutropenia secondary to C with G-CSF in
MM patients undergoing SC transplantation. Subgroup
analysis was done comparing patients greater than 70 years
and younger.
Methods: We retrospectively reviewed charts of all pa-
tients with MM who mobilized using C with G-CSF at
UMass Memorial Medical Center from January 2009 to
June 2014.
Results: Fifty-six patients were identiﬁed from the stem cell
transplant database. There were 36 males (64%) and 20 fe-
males (36%). Median age was 62 years (range 43 - 79). The
median C dose received was 2548 mg/m2 (range 1318 -
4018mg/m2). The median total CD34 collection was 15.07 x
10e6/kg (range 2.71-113). Median time from C infusion to SC
collection was 10 days (range 10-16). Number of days
required for collection was 1(n¼40), 2 (n¼14) and 3 (n¼2).
Three patients received plerixafor prior to day 2 collection.
Median days of documented neutropenia was 1 (range 0-6).
Only 3 (5.3%) patients were hospitalized for NF requiring
intravenous antibiotics. Optimal collection for two trans-
plants (>10x 10e6 CD34/kg) was achieved in 43 (77%)
patients.
12 patients (21%) were over age 70 years. In comparison
with the younger patient, they were noted to receive lower
median dose of C (1988mg/m2 vs. 2714mg/m2, p value2000-3000mg/m2 >3000mg/m2 p-value
62.5 (43-77) 60.5 (48-68) 0.5905
22 16 -
2584 (2001-2994) 3788 (3033-4018) 0.0001
15.72 (2.71- 36.6) 16.10 (5.27 e 113) 0.6717
10 (10-13) 11 (10-16) 0.0031
2 (0-6) 3 (0-6) 0.0003
1 2 0.2712
